MedPage Today on MSN2d
Initiating Systemic Therapy for PsoriasisUntil about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
First for Women on MSN3d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Verywell Health on MSN10d
How to Tell If You May Have Scalp Psoriasis vs. DandruffScalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...
Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...
Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...
UCB's Bimzelx shows sustained efficacy in psoriasis and hidradenitis suppurativa, with high skin clearance rates and improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback